Comparing skipping radiation after surgery for early-stage DCIS
Treatments studied
Part of Cancer clinical trials.
This trial compares skipping radiation therapy after breast-conserving surgery for low- or intermediate-risk ductal carcinoma in situ (DCIS) – a very early, non-invasive breast cancer. It aims to see if omitting radiation is as effective as standard treatment while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 40 or older.
- You have low- or intermediate-grade ductal carcinoma in situ (DCIS) – a non-invasive breast condition.
- The cancer is estrogen receptor (ER) positive, and you plan to take tamoxifen.
- Your tumor is 2.5 cm or smaller and was removed with clear margins (at least 3 mm).
- You have not had breast cancer in the other breast, and do not have a BRCA gene mutation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at whether it is safe for younger women who have had surgery for a very early-stage, low-risk breast condition called DCIS to skip radiation therapy. The goal is to see if they can avoid the side effects of radiation without the cancer coming back.
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
This trial studies giving radiation during surgery for women with a certain early breast condition called ductal carcinoma in situ (DCIS). It may help lower the chance that the DCIS comes back, especially when combined with breast-conserving surgery.
This trial compares two approaches for ductal carcinoma in situ (DCIS): having surgery first versus getting radiation first and then having surgery later. It aims to see which plan controls DCIS better while affecting treatment timing and outcomes.
This trial tests whether older women with very low-risk, hormone-positive breast cancer can safely skip endocrine therapy (hormone-blocking pills) and radiation after lumpectomy. It aims to maintain quality of life while keeping cancer from coming back.
This trial is for women aged 55 or older with very early-stage breast cancer (stage 0 or 1) who want to save their breast. It tests giving a single dose of radiation during the lumpectomy instead of weeks of daily radiation afterward.
Hear when a new Ductal Carcinoma In Situ, DCIS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.